Edition:
United States

Synlogic Inc (SYBX.OQ)

SYBX.OQ on NASDAQ Stock Exchange Global Market

10.23USD
14 Dec 2017
Change (% chg)

$-0.03 (-0.29%)
Prev Close
$10.26
Open
$10.21
Day's High
$11.00
Day's Low
$10.21
Volume
20,077
Avg. Vol
5,291
52-wk High
$23.00
52-wk Low
$8.83

Summary

Name Age Since Current Position

Michael Powell

62 2012 Chairman of the Board

Jose Gutierrez-Ramos

2017 President, Chief Executive Officer, Director

Todd Shegog

2017 Chief Financial Officer, Secretary

Andrew Gengos

53 2017 Chief Operating Officer - Head of Corporate Development

Paul Miller

2017 Chief Scientific Officer

Jay Stoudemire

2015 Vice President - Preclinical Development, Regulatory and Quality Assurance

Aoife Brennan

2017 Chief Medical Officer

Casi DeYoung

46 2014 Chief Business Officer

Edward Mathers

57 2012 Independent Director

Biographies

Name Description

Michael Powell

Dr. Michael F. Powell, Ph.D. is the Chairman of the Board of the Company. Dr. Powell has served as Chairman of our board of directors since October 2012. Since 1997, Dr. Powell has been a General Partner of Sofinnova Ventures, a venture capital firm. Previously, Dr. Powell has held positions at Genentech, Inc., a biotechnology company, Cytel, a research and development company, and Syntex Research Group, a pharmaceutical company. Dr. Powell is currently a director of Dauntless Pharmaceuticals, a biopharmaceutical company, Alvine Pharmaceuticals, a biopharmaceutical company, Ascenta Therapeutics, a biopharmaceutical company, Checkmate Pharmaceuticals, a biopharmaceutical company, Dauntless 1, a biopharmaceutical company, and Ocera Therapeutics, a publicly traded biopharmaceutical company. Dr. Powell is an Adjunct Professor at the University of Kansas. Dr. Powell is the Board President of the AIDS Vaccine Advocacy Coalition and serves on the advisory board of the Institute for the Advancement of Medical Innovation at the University of Kansas. Dr. Powell received a B.S. in Chemistry from Scarborough College, a Ph.D. in Physical Chemistry from the University of Toronto and completed his post-doctorate work in Bioorganic Chemistry at the University of California.

Jose Gutierrez-Ramos

Todd Shegog

Andrew Gengos

Mr. Andrew W. Gengos is Chief Operating Officer - Head of Corporate Development of the Company. Mr. Gengos most recently served as President, Chief Executive Officer and as a director of ImmunoCellular Therapeutics, a publicly-traded immune-oncology company pursuing treatments for glioblastoma from December 2012 to December 2016. Previously, Mr. Gengos was the President and Chief Executive Officer of Neuraltus Pharmaceuticals from February 2010 to August 2012. Prior to his service with Neuraltus, Mr. Gengos served for more than seven years with Amgen where, as Vice President, Strategy and Corporate Development, he managed Amgen’s worldwide in-and-outbound business development activities, including a broad slate of acquisitions, licensing, spin-outs, divestitures, corporate venture capital investments, which included board of director positions and alliance management. In addition, he led the execution of strategic projects and supported the long-range planning process for the company. Before joining Amgen, Mr. Gengos was Vice President, Chief Financial Officer, and Chief Business Officer of Dynavax Technologies, where he led the company’s business functions, including finance and accounting, fundraising, budgeting and planning, and business development. Earlier in his career, Mr. Gengos served as Vice President of Strategy at the Chiron Corporation and as Senior Engagement Manager at McKinsey & Company. Mr. Gengos holds an M.B.A. from the UCLA Anderson School of Management and a B.S. in chemical engineering from the Massachusetts Institute of Technology.

Paul Miller

Jay Stoudemire

Dr. Jay Stoudemire, Ph.D. serves as Vice President - Preclinical Development, Regulatory and Quality Assurance of the Company. Prior to joining Mirna in 2010, he has held positions at Genentech, Ascenta Therapeutics, Chugai-Roche Pharmaceuticals, Cytel, Genetics Institute, and Xoma, with responsibility for the pharmacokinetic and toxicological evaluations of a range of small molecules and biologics, including cytokines, growth and hematopoietic factors, monoclonal antibodies and pro-apoptotic therapeutics. Dr. Stoudemire received his Ph.D. in microbiology from the University of Miami and completed a postdoctoral fellowship in the Cardiovascular Research Institute at the University of California San Francisco.

Aoife Brennan

Casi DeYoung

Ms. Casi DeYoung serves as Chief Business Officer of the Company., since March 2014. From May 2008 to December 2013, Ms. DeYoung served as the Vice President of Business Development for Reata Pharmaceuticals, Inc., a biopharmaceutical company. Previously, Ms. DeYoung served as the Vice President of Business Development for ODC Therapy, Inc., an immunotherapy company. From 2000 to 2005, Ms. DeYoung served in various roles, including the Director of Global Oncology Operations, for EMD Pharmaceuticals, Inc., the U.S. affiliate of Merk KGaA, a global healthcare company. Ms. DeYoung received a B.S. in Chemistry from Southwestern University and an M.B.A. from the University of Texas at Austin.

Edward Mathers

Mr. Edward T. Mathers is an Independent Director of the Company. Mr. Mathers has served as a member of our board of directors since October 2012. Since August 2008, Mr. Mathers has been a Partner at New Enterprise Associates, Inc., or NEA, a private venture capital firm focusing on technology and healthcare investments. Mr. Mathers serves on the board of directors of the following pharmaceutical companies: Amplyx Pharmaceuticals, Inc., ObsEva SA, SunLogic, LLC, Ziarco Group Limited, Envisia Therapeutics, Inc., Ra Pharmaceuticals, Inc., Rhythm Pharmaceuticals, and Lumos Pharma. Mr. Mathers also serves on the board of directors of Liquidia Technologies, a biotechnology company. From 2002 to 2008, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune, Inc., or MedImmune, the global biologics arm of AstraZeneca, a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, a biotechnology company. Previously, Mr. Mathers spent 15 years at Glaxo Wellcome, Inc. (now GlaxoSmithKline plc), a pharmaceutical company, where he held various sales and marketing positions. Mr. Mathers received a B.S. in Chemistry from North Carolina State University.